Cardiol Therapeutics Achieves 50% Patient Enrollment in Pivotal Phase III MAVERIC Trial

summarizeResumen

This milestone is highly significant for Cardiol Therapeutics as it de-risks the development timeline and increases the probability of success for its lead registrational program. Reaching 50% enrollment in a pivotal Phase III trial demonstrates strong operational execution and investigator confidence in CardiolRx™ for recurrent pericarditis, an underserved patient population. The company anticipates completing full enrollment in Q2 2026, which provides a clear path towards potential regulatory submission and commercialization.

check_boxEventos clave

• 50% Patient Enrollment Achieved

  Cardiol Therapeutics has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial evaluating CardiolRx™ for recurrent pericarditis.

• Key De-risking Milestone

  This enrollment milestone represents a significant execution and risk-reduction inflection point for the company's lead registrational program.

• Full Enrollment Expected Q2 2026

  The company anticipates completing full patient enrollment in the MAVERIC trial by the second quarter of 2026.

• Expanding Clinical Infrastructure

  More than 15 leading cardiovascular centers in the U.S. are actively enrolling patients, with additional sites in Europe and Canada being activated to accelerate momentum.

auto_awesomeAnalisis

This milestone is highly significant for Cardiol Therapeutics as it de-risks the development timeline and increases the probability of success for its lead registrational program. Reaching 50% enrollment in a pivotal Phase III trial demonstrates strong operational execution and investigator confidence in CardiolRx™ for recurrent pericarditis, an underserved patient population. The company anticipates completing full enrollment in Q2 2026, which provides a clear path towards potential regulatory submission and commercialization.